Amneal Pharmaceuticals Reaps $2.5M in Kentucky Incentives
"In addition to compelling economic incentives, we recognized that the superb quality and dedication of Glasgow's work force is a key factor in Amneal's reputation for service excellence, so the decision to stay and expand operations in Kentucky was an easy one," said Jim Luce, Amneal executive vice president of sales and marketing.
The Kentucky Economic Development Finance Authority has pre-approved Amneal for tax incentives up to $2.5 million through the Kentucky Business Investment program.
Amneal plans to use the funds to consolidate distribution logistics and sales in a 115,000-square-foot Glasgow facility. It will combine distribution that currently exists in Long Island, New York and Fountain Run, Kentucky. The company develops, manufactures, and distributes generic pharmaceuticals. It is the tenth largest supplier of generic drugs in the country in terms of prescriptions dispensed.
2022 Top States for Doing Business Provide an Environment for Business Growth
Location Factors in the EV Industry — “Mission Critical” or “Nice to Have”?
2022 Auto/Aero Site Guide
Three Big Challenges Facing the Food & Beverage Industry
How Are Economic Developers Partnering to Solve Workforce Challenges?
36th Annual Corporate Survey: Executives Focus on Labor, Energy, Shipping Costs
Fixing the Supply Chain with AI and Robotics
18th Annual Consultants Survey: Access to Major Markets and Skilled Labor Are Clients’ Primary Concerns